Bioventus Inc.
BVS
$7.51
-$0.09-1.14%
NASDAQ
| 09/27/2025 | 06/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -6.10% | 19.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.10% | 19.20% | |||
| Cost of Revenue | -2.52% | 11.64% | |||
| Gross Profit | -7.70% | 22.92% | |||
| SG&A Expenses | -0.57% | 7.65% | |||
| Depreciation & Amortization | -2.85% | -9.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.46% | 8.73% | |||
| Operating Income | -38.72% | 269.64% | |||
| Income Before Tax | -54.72% | 401.81% | |||
| Income Tax Expenses | -36.22% | 1,195.79% | |||
| Earnings from Continuing Operations | -56.79% | 379.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 53.06% | -364.67% | |||
| Net Income | -57.70% | 382.86% | |||
| EBIT | -38.72% | 269.64% | |||
| EBITDA | -25.51% | 80.73% | |||
| EPS Basic | -58.02% | 381.20% | |||
| Normalized Basic EPS | -51.15% | 432.38% | |||
| EPS Diluted | -57.18% | 375.69% | |||
| Normalized Diluted EPS | -51.11% | 422.38% | |||
| Average Basic Shares Outstanding | 0.64% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.44% | 3.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||